L Borgstrom, E Derom, E Stahl, E Wahlin-Boll and R Pauwels
Astra Draco AB, Lund, Sweden.

The development of new inhalation devices for asthma drugs raises the issue of the relationship between pulmonary deposition and therapeutic effect of inhaled drugs in patients with obstructive lung diseases. We thus conducted a randomized, double-blind and double-dummy, four-period crossover study in 13 patients with moderate asthma (mean age 36 yr; FEV1 59% of predicted), who inhaled 0.25 and 0.5 mg terbutaline sulphate on separate occasions either via a pressurized metered dose inhaler (pMDI) or Turbuhaler (TBH). Pulmonary deposition was 8.1 +/- 2.7% and 8.3 +/- 2.3%, respectively, of the nominal dose for pMDI and 19.0 +/- 7.3%, and 22.0 +/- 8.1% for TBH. The FEV1 increase after 0.25 mg terbutaline sulphate via TBH was significantly greater than after 0.25 mg via pMDI. No significant differences in FEV1 increase were observed between 0.25 mg via TBH, 0.5 mg via pMDI, or 0.5 mg via TBH. Other lung function variables showed similar dose- and device-related changes. We concluded that: (1) the dose of terbutaline sulphate deposited in the lungs is dependent on which inhalation system is used; (2) TBH delivers about twice the amount of drug to the lungs as the pMDI; and (3) the observed difference in deposition is reflected in the bronchodilating effect.

This article has been cited by other articles:

				Inhalation devices Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45. [Full Text] [PDF]

				L. Agertoft and S. Pedersen Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782. [Abstract] [Full Text] [PDF]

				S Drblik, G Lapierre, R Thivierge, J Turgeon, P Gaudreault, B Cummins-McManus, I Verdy, J Haddon, J Lee, and S Spier Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode Arch. Dis. Child., April 1, 2003; 88(4): 319 - 323. [Abstract] [Full Text] [PDF]

				F. S F Ram, J. Wright, D. Brocklebank, and J. E S White Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma BMJ, October 20, 2001; 323(7318): 901 - 901. [Abstract] [Full Text]

				E. DEROM, L. BORGSTROM, J. VAN SCHOOR, A.-B. LOFROOS, and R. PAUWELS Lung Deposition and Protective Effect of Terbutaline Delivered from Pressurized Metered-Dose Inhalers and the Turbuhaler in Asthmatic Individuals Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1398 - 1402. [Abstract] [Full Text] [PDF]

				P. J. Anderson Delivery Options and Devices for Aerosolized Therapeutics Chest, September 1, 2001; 120(3_suppl): 89S - 93S. [Abstract] [Full Text] [PDF]

				D. FISHWICK, L. BRADSHAW, C. MACDONALD, R. BEASLEY, D. GASH, T. BENGTSSON, E. BONDESSON, and L. BORGSTRÖM Cumulative and Single-dose Design to Assess the Bronchodilator Effects of {beta}2-Agonists in Individuals with Asthma Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 474 - 477. [Abstract] [Full Text]

				D. Giannini, A. Di Franco, E. Bacci, F. L. Dente, M. Taccola, B. Vagaggini, and P. Paggiaro The Protective Effect of Salbutamol Inhaled Using Different Devices on Methacholine Bronchoconstriction Chest, May 1, 2000; 117(5): 1319 - 1323. [Abstract] [Full Text] [PDF]

				M. G. Cochrane, M. V. Bala, K. E. Downs, J. Mauskopf, and R. H. Ben-Joseph Inhaled Corticosteroids for Asthma Therapy: Patient Compliance, Devices, and Inhalation Technique Chest, February 1, 2000; 117(2): 542 - 550. [Abstract] [Full Text] [PDF]

				D A Hughes, A Woodcock, and T Walley Review of therapeutically equivalent alternatives to short acting beta 2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers Thorax, December 1, 1999; 54(12): 1087 - 1092. [Abstract] [Full Text]

				A. MELLEN, P. ARVIDSSON, M. PALMQVIST, and J. LOTVALL Equivalent Bronchodilation with Salbutamol Given via pMDI or Turbuhaler Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1663 - 1665. [Abstract] [Full Text] [PDF]

				T W Harrison, J Oborne, P J Wilding, and A E Tattersfield Randomised placebo controlled trial of beta  agonist dose reduction in asthma Thorax, February 1, 1999; 54(2): 98 - 102. [Abstract] [Full Text]

				P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]

				R. A. Pauwels, C.-G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, A. Ullman, and The Formoterol and Corticosteroids Establishing Th Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma N. Engl. J. Med., November 13, 1997; 337(20): 1405 - 1411. [Abstract] [Full Text] [PDF]

				H. Bisgaard Drug delivery from inhaler devices BMJ, October 12, 1996; 313(7062): 895 - 896. [Full Text]